Treatment outcomes in ovarian cancer patients with BRCA mutations at K Hospital

Abstract

BRCA1/2 mutations are associated with various aspects of ovarian cancer, including the age of onset, histopathology, response to treatment, and prognosis. Patients with BRCA1/2 mutations often have rapid disease progression, resulting in a shorter survival time. In modern medicine, detecting and personalizing treatment for patients with BRCA1/2 mutations is crucial, not only to improve prognosis but also to increase the overall survival time. This retrospective descriptive study was conducted on 35 patients with ovarian epithelial cancer and BRCA1/2 mutations treated at K Hospital from April 2022 to April 2023. Most patients were over 50 years old (60%). There were three patients with a history of breast cancer and three patients with a family history of sisters diagnosed with breast or ovarian cancer. Most of the initial diagnoses were at stage III (74.2%), with high-grade serous carcinoma accounting for the highest percentage (94.4%). BRCA1 mutations were predominant, accounting for 71.4%, with common mutations including 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2. The most common treatment approach was surgery, followed by chemotherapy (37.2%). The median disease-free survival (DFS) was 14.6 months. Patients receiving maintenance therapy with angiogenesis inhibitors or PARP inhibitors tended to have improved DFS. Patients with BRCA1/2 mutations respond better to systemic treatment than those without mutations, particularly with targeted therapies such as PARP inhibitors. The application of personalized treatment strategies for ovarian cancer patients with BRCA1/2 mutations is a promising and necessary approach.